Biohaven Ltd. (BHVN) shareholders
Close on Nov 18, 2026Market cap $1.95BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 17,534,612 | 11.70% | 13G (passive) amendment | Mar 31, 2026 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (7.80%), Averill Master Fund, Ltd. (6.60%) | 10,286,937 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
| JANUS HENDERSON GROUP Ltd. | 8,584,676 | 5.70% | 13G (passive) amendment | Jun 30, 2026 |
| Woodline Partners LP | 7,660,280 | 5.10% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 5,762,738 | 7.20% | 13G (passive) | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BHVN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,210,585 | 8.75% | $196.57M | +1,988,178 | 0.00% |
| Suvretta Capital Management, LLC | 10,286,937 | 6.81% | $153.07M | – | 2.80% |
| Stifel Financial Corp | 9,941,165 | 6.58% | $147.92M | +280 | 0.12% |
| Jupiter Topco LLC | 8,584,675 | 5.68% | $127.85M | New | 0.05% |
| Woodline Partners LP | 7,660,280 | 5.07% | $113.98M | +7,359,891 | 0.35% |
| State Street Corp | 6,947,034 | 4.60% | $103.37M | +328,231 | 0.00% |
| Infinitum Asset Management, LLC | 6,250,000 | 4.14% | $93.00M | – | 9.46% |
| D. E. Shaw & Co., Inc. | 4,190,195 | 2.77% | $62.35M | +1,343,002 | 0.03% |
| Aqr Capital Management LLC | 4,150,616 | 2.75% | $61.76M | +2,175,100 | 0.02% |
| Geode Capital Management, LLC | 3,323,190 | 2.20% | $49.46M | +555,427 | 0.00% |
| FMR LLC | 2,964,630 | 1.96% | $44.11M | +605,583 | 0.00% |
| Royalty Pharma Sub-Manager, LLC | 2,936,507 | 1.94% | $43.70M | – | 18.06% |
| Cormorant Asset Management, LP | 2,610,000 | 1.73% | $38.84M | +850,000 | 1.99% |
| Goldman Sachs Group Inc | 2,583,046 | 1.71% | $38.44M | +69,865 | 0.00% |
| UBS Group AG | 2,518,827 | 1.67% | $37.48M | +1,092,400 | 0.00% |
| Vanguard Portfolio Management LLC | 2,488,941 | 1.65% | $37.04M | +209,666 | 0.00% |
| Balyasny Asset Management L.P. | 1,879,734 | 1.24% | $27.97M | −565,682 | 0.03% |
| TCG Crossover Management, LLC | 1,779,952 | 1.18% | $26.49M | −2,851,365 | 0.64% |
| Nuveen, LLC | 1,744,334 | 1.15% | $25.96M | +998,586 | 0.01% |
| Rubric Capital Management LP | 1,721,493 | 1.14% | $25.62M | New | 0.23% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 294 | 141M | 93.4% | 52 / 109 | 87 / 31 | 36M | 21M |
| Q1 2026 | 277 | 144M | 95.1% | 44 / 118 | 64 / 34 | 39M | 11M |
| Q4 2025 | 273 | 122M | 80.4% | 72 / 117 | 55 / 57 | 56M | 20M |
| Q3 2025 | 264 | 86M | 56.7% | 50 / 89 | 73 / 32 | 17M | 19M |
| Q2 2025 | 249 | 87M | 57.7% | 38 / 96 | 70 / 52 | 15M | 19M |
| Q1 2025 | 265 | 91M | 60.4% | 48 / 95 | 75 / 36 | 8M | 7M |
| Q4 2024 | 256 | 92M | 61.1% | 47 / 103 | 64 / 41 | 12M | 7M |
| Q3 2024 | 254 | 87M | 57.6% | 53 / 77 | 80 / 23 | 17M | 7M |
| Q2 2024 | 225 | 83M | 55.2% | 40 / 100 | 50 / 56 | 16M | 9M |
| Q1 2024 | 243 | 76M | 50.3% | 56 / 73 | 71 / 30 | 13M | 10M |
| Q4 2023 | 218 | 73M | 48.0% | 58 / 77 | 46 / 26 | 18M | 7M |
| Q3 2023 | 187 | 61M | 40.7% | 22 / 63 | 67 / 22 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
57 funds held BHVN in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BHVN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1,489,215 | 0.99% | $22.16M | 0.02% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,168,175 | 0.77% | $17.38M | 0.02% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 826,340 | 0.55% | $11.16M | 0.27% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 603,592 | 0.40% | $6.65M | 0.04% | May 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 508,214 | 0.34% | $7.56M | 0.01% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 490,599 | 0.32% | $7.30M | 0.06% | Jun 30, 2026 |
| Vanguard Explorer Fund | 485,893 | 0.32% | $6.56M | 0.03% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 392,136 | 0.26% | $4.32M | 0.02% | May 31, 2026 |
| Nuveen Quant Small/Mid Cap Equity Fund | 382,100 | 0.25% | $5.16M | 0.19% | Jul 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 236,037 | 0.16% | $3.19M | 0.12% | Jul 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 176,731 | 0.12% | $2.39M | 0.06% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 129,647 | 0.09% | $1.93M | 0.06% | Jun 30, 2026 |
| Direxion Daily S&P Biotech Bull 3X Shares | 128,814 | 0.09% | $1.74M | 0.35% | Jul 31, 2026 |
| Nuveen ESG Small-Cap ETF | 120,245 | 0.08% | $1.62M | 0.13% | Jul 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 110,695 | 0.07% | $1.22M | 0.07% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Vlad Coric | Chief Executive Officer, Director | 3,856,784 | 2.55% | Mar 3, 2026 |
| Kimberly Gentile | SVP, Clinical Operations | 101,513 | 0.07% | Sep 17, 2026 |
| Warren Karl Volles | Chief Legal Officer | 248,212 | 0.16% | Jul 17, 2026 |
| George C. Clark | VP, Chief Accounting Officer | 86,978 | 0.06% | Mar 3, 2026 |
| Bruce Car | Chief Scientific Officer | 40,096 | 0.03% | Mar 3, 2026 |
| Matthew Buten | Chief Financial Officer | 198,246 | 0.13% | Mar 3, 2026 |
| John Yetimoglu | Director | 6,250,000 | 4.14% | Aug 14, 2026 |
| Gregory Bailey | Director | 2,020,071 | 1.34% | Apr 30, 2026 |
| John W. Childs | Director | 8,088,392 | 5.35% | Apr 30, 2026 |
| Kishan Mehta | Director | 22,662 | 0.02% | Apr 30, 2026 |
| Irina Antonijevic | Director | 2,535 | 0.00% | Apr 30, 2026 |
| Michael Thomas Heffernan | Director | 15,178 | 0.01% | Apr 30, 2026 |
| Robert J. Hugin | Director | 12,959 | 0.01% | Apr 30, 2026 |
| Julia P. Gregory | Director | 25,665 | 0.02% | Apr 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kishan Mehta Director | Mar 17, 2026 | Gift | +17,342 | – | – | 17,342 |
| Kishan Mehta Director | Mar 17, 2026 | Gift | −17,342 | – | – | 5,320 |
| George C. Clark VP, Chief Accounting Officer | Jan 5, 2026 | Tax withholding | −1,117 | $9.93 | $11.09K | 66,978 |
| George C. Clark VP, Chief Accounting Officer | Jan 5, 2026 | Option exercise | +2,500 | – | – | 68,095 |
| Matthew Buten Chief Financial Officer | Jan 5, 2026 | Option exercise | +4,250 | – | – | 198,246 |
| Matthew Buten Chief Financial Officer | Jan 5, 2026 | Tax withholding | −2,594 | $9.93 | $25.76K | 195,652 |
| Kimberly Gentile SVP, Clinical Operations | Jan 5, 2026 | Option exercise | +3,750 | – | – | 101,513 |
| Kimberly Gentile SVP, Clinical Operations | Jan 5, 2026 | Tax withholding | −1,956 | $9.93 | $19.42K | 99,557 |
| Bruce Car Chief Scientific Officer | Jan 5, 2026 | Option exercise | +4,750 | – | – | 10,096 |
| Bruce Car Chief Scientific Officer | Jan 5, 2026 | Tax withholding | −2,381 | $9.93 | $23.64K | 7,715 |
| Vlad Coric Chief Executive Officer, Director | Jan 5, 2026 | Option exercise | +14,250 | – | – | 1,811,398 |
| Vlad Coric Chief Executive Officer, Director | Jan 5, 2026 | Tax withholding | −7,430 | $9.93 | $73.78K | 1,803,968 |
| George C. Clark VP, Chief Accounting Officer | Nov 17, 2025 | Buy | +17,000 | $8.52 | $144.84K | 20,000 |
| Vlad Coric Chief Executive Officer, Director | Nov 13, 2025 | Buy | +333,333 | $7.50 | $2.50M | 1,195,275 |
| Vlad Coric Chief Executive Officer, Director | Nov 13, 2025 | Buy | +333,333 | $7.50 | $2.50M | 740,546 |
| John W. Childs Director | Nov 13, 2025 | Buy | +3,333,333 | $7.50 | $25.00M | 5,653,904 |
| Gregory Bailey Director | Nov 13, 2025 | Buy | +400,000 | $7.50 | $3.00M | 2,020,071 |
| John W. Childs Director | Mar 4, 2025 | Buy | +28,400 | $30.43 | $864.21K | 2,323,971 |
| John W. Childs Director | Mar 4, 2025 | Buy | +25,000 | $30.39 | $759.75K | 2,320,571 |
| John W. Childs Director | Mar 4, 2025 | Buy | +3,400 | $30.73 | $104.48K | 24,452 |
| John W. Childs Director | Mar 4, 2025 | Buy | +3,400 | $30.73 | $104.48K | 76,570 |
| John W. Childs Director | Mar 4, 2025 | Buy | +900 | $30.73 | $27.66K | 25,291 |
| Vlad Coric Chief Executive Officer, Director | Jan 5, 2025 | Option exercise | +14,250 | – | – | 1,803,409 |
| Vlad Coric Chief Executive Officer, Director | Jan 5, 2025 | Tax withholding | −6,805 | $38.64 | $262.95K | 1,796,604 |
| George C. Clark VP, Chief Accounting Officer | Jan 5, 2025 | Option exercise | +2,500 | – | – | 66,168 |
| George C. Clark VP, Chief Accounting Officer | Jan 5, 2025 | Tax withholding | −1,117 | $38.64 | $43.16K | 65,051 |
| Bruce Car Chief Scientific Officer | Jan 5, 2025 | Option exercise | +4,750 | – | – | 7,133 |
| Bruce Car Chief Scientific Officer | Jan 5, 2025 | Tax withholding | −2,331 | $38.64 | $90.07K | 4,802 |
| Matthew Buten Chief Financial Officer | Jan 5, 2025 | Option exercise | +4,250 | – | – | 196,013 |
| Matthew Buten Chief Financial Officer | Jan 5, 2025 | Tax withholding | −2,561 | $38.64 | $98.96K | 193,452 |
| Kimberly Gentile SVP, Clinical Operations | Jan 5, 2025 | Option exercise | +3,750 | – | – | 99,719 |
| Kimberly Gentile SVP, Clinical Operations | Jan 5, 2025 | Tax withholding | −1,956 | $38.64 | $75.58K | 97,763 |
| John W. Childs Director | Dec 30, 2024 | Buy | +29,000 | $35.94 | $1.04M | 2,368,741 |
| John W. Childs Director | Oct 2, 2024 | Buy | +21,052 | $47.50 | $999.97K | 21,052 |
| Vlad Coric Chief Executive Officer, Director | Oct 2, 2024 | Buy | +21,052 | $47.50 | $999.97K | 861,942 |
| Gregory Bailey Director | Sep 24, 2024 | Buy | +5,000 | $44.19 | $220.95K | 1,620,071 |
| John W. Childs Director | Jul 18, 2024 | Buy | +28,400 | $35.67 | $1.01M | 2,339,741 |
| Bruce Car Chief Scientific Officer | Jun 17, 2024 | Buy | +30,000 | $33.58 | $1.01M | 30,000 |
| John W. Childs Director | May 30, 2024 | Buy | +28,000 | $35.58 | $996.24K | 2,311,341 |
| Gregory Bailey Director | May 13, 2024 | Buy | +15,000 | $34.19 | $512.85K | 1,615,071 |
| John W. Childs Director | May 13, 2024 | Buy | +28,500 | $35.17 | $1.00M | 2,283,341 |
| Gregory Bailey Director | Apr 24, 2024 | Buy | +25,503 | $39.18 | $999.21K | 1,600,071 |
| John W. Childs Director | Apr 22, 2024 | Buy | +73,170 | $41.00 | $3.00M | 73,170 |
| Vlad Coric Chief Executive Officer, Director | Apr 22, 2024 | Buy | +121,951 | $41.00 | $5.00M | 1,788,417 |
| John W. Childs Director | Apr 22, 2024 | Buy | +24,391 | $41.00 | $1.00M | 24,391 |
| John W. Childs Director | Apr 22, 2024 | Buy | +73,170 | $41.00 | $3.00M | 2,254,841 |
| John W. Childs Director | Apr 22, 2024 | Buy | +97,560 | $41.00 | $4.00M | 4,096,512 |
| Gregory Bailey Director | Apr 22, 2024 | Buy | +48,780 | $41.00 | $2.00M | 1,574,568 |
| Vlad Coric Chief Executive Officer, Director | Apr 5, 2024 | Award | +231 | – | – | 840,890 |
| Vlad Coric Chief Executive Officer, Director | Apr 5, 2024 | Award | +232 | – | – | 1,666,466 |
| Vlad Coric Chief Executive Officer, Director | Apr 5, 2024 | Award | +231 | – | – | 407,213 |
| John W. Childs Director | Apr 5, 2024 | Award | +2,091 | – | – | 2,181,671 |
| Vlad Coric Chief Executive Officer, Director | Mar 8, 2024 | Award | +2,155 | – | – | 840,659 |
| Vlad Coric Chief Executive Officer, Director | Mar 8, 2024 | Award | +2,155 | – | – | 406,982 |
| Vlad Coric Chief Executive Officer, Director | Mar 8, 2024 | Award | +2,162 | – | – | 1,666,234 |
| John W. Childs Director | Mar 8, 2024 | Award | +19,412 | – | – | 2,179,580 |
| John W. Childs Director | Jan 8, 2024 | Other | +48,505 | – | – | 2,160,168 |
| Vlad Coric Chief Executive Officer, Director | Jan 8, 2024 | Award | +5,384 | – | – | 404,827 |
| Vlad Coric Chief Executive Officer, Director | Jan 8, 2024 | Award | +5,384 | – | – | 838,504 |
| Vlad Coric Chief Executive Officer, Director | Jan 8, 2024 | Award | +5,400 | – | – | 1,662,431 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Biohaven's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1 shares on Aug 25, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Irina Antonijevic Director | Dec 29, 2023 | 11,000 | $459.66K | Dec 29, 2023 | STOCK OPTION EXERCISE |
See a number that looks wrong?